Evidence map›Paper›PMID 36430502›Full record

ArticleInternational journal of molecular sciences2022

5-HT

Hongmei Dai, Yoshikazu Kitami, Yu-Ichi Goto, Masayuki Itoh

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hongmei DaiDepartment of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
Yoshikazu KitamiDepartment of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
Yu-Ichi GotoDepartment of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
Masayuki ItohDepartment of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.ORCID 0000-0001-7247-2259
National Center of Neurology and Psychiatry · JP

Funding

Health Labour Sciences Research of the Ministry of Health, Labour and Welfare 20FC1002 and 20FC1019Intramural Research Grants for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry N/AJapan Agency for Medical Research and Development 20ek0109389h0003Wellcome Trust FC001002
6 · The paper itself

Abstract

Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused by mutations in the gene that encodes methyl CpG-binding protein 2 (MECP2) and is characterized by the loss of acquired motor and language skills, stereotypic movements, respiratory abnormalities and autistic features. There has been no effective treatment for this disorder until now. In this study, we used a

Indexed as

Rett SyndromeAnimalsBrain-Derived Neurotrophic FactorMethyl-CpG-Binding Protein 2MiceMice, KnockoutNeuronsPhenotypeReceptor, Serotonin, 5-HT1ASerotonin Receptor AgonistsSynaptic TransmissionBrain-Derived Neurotrophic FactorMecp2 protein, mouseMethyl-CpG-Binding Protein 2Receptor, Serotonin, 5-HT1ASerotonin Receptor Agonists5-HT1A receptorneurotransmitterRett syndrometandospirone

Identifiers

PMID36430502
PMCPMC9697184
OpenAlexW4309007625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.